Investing in Adicet Bio, Inc. (ACET)  ➔  Intrinsic value

Prev. close$8.04 
ModelValueUpside
Chepakovich$3.65-55%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$8.04  
Valuation MethodValuePotential 
Chepakovich Model$3.65-55%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California.